Herceptin, the only anti-ErbB2, humanised monoclonal antibody approved by FDA for therapy of mammary carcinoma is currently and successfully prescribed for treatment of ErbB2-positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.